FIXX Key Statistics, Chart & Performance
The current stock price of FIXX is 0.9347 USD. In the past month the price increased by 4.8%. In the past year, price decreased by -9.25%.
FIXX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About FIXX
Company Profile
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.
Company Info
HOMOLOGY MEDICINES INC
1 Patriots Park
Bedford MASSACHUSETTS 01730 US
CEO: Arthur O. Tzianabos
Employees: 92
Phone: 17813017277
HOMOLOGY MEDICINES INC / FIXX FAQ
What does FIXX do?
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.
What is the stock price of HOMOLOGY MEDICINES INC today?
The current stock price of FIXX is 0.9347 USD. The price increased by 0.77% in the last trading session.
What is the dividend status of HOMOLOGY MEDICINES INC?
FIXX does not pay a dividend.
What is the ChartMill technical and fundamental rating of FIXX stock?
FIXX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does HOMOLOGY MEDICINES INC have?
HOMOLOGY MEDICINES INC (FIXX) currently has 92 employees.
What is HOMOLOGY MEDICINES INC worth?
HOMOLOGY MEDICINES INC (FIXX) has a market capitalization of 54.23M USD. This makes FIXX a Micro Cap stock.
FIXX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FIXX. When comparing the yearly performance of all stocks, FIXX is one of the better performing stocks in the market, outperforming 81.09% of all stocks.
FIXX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FIXX. FIXX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FIXX Financial Highlights
Over the last trailing twelve months FIXX reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS decreased by -3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.57% | ||
| ROE | -154.74% | ||
| Debt/Equity | 0 |
FIXX Forecast & Estimates
6 analysts have analysed FIXX and the average price target is 1.53 USD. This implies a price increase of 63.69% is expected in the next year compared to the current price of 0.9347.
For the next year, analysts expect an EPS growth of 64.09% and a revenue growth -100% for FIXX